About Type 2 phosphatidylinositol 4,5-bisphosphate 4-phosphatase
Type 2 phosphatidylinositol 4,5-bisphosphate 4-phosphatase (PIP4P2) is a protein
from Homo sapiens identified by UniProt accession
Q8N4L2, 257 residues long.
MolForge cross-references it against 0 known binders and
19 disease associations.
Target properties
| Protein name | Type 2 phosphatidylinositol 4,5-bisphosphate 4-phosphatase |
|---|
| UniProt accession | Q8N4L2 |
|---|
| Gene | PIP4P2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 257 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (19)
Diseases linked to this target (Open Targets).
- age at first sexual intercourse measurement · score 0.20
- self reported educational attainment · score 0.15
- body fat percentage · score 0.15
- smoking status measurement · score 0.13
- appendicular lean mass · score 0.12
- hemoglobin measurement · score 0.11
- smoking initiation · score 0.10
- hematocrit · score 0.05
- smoking behaviour measurement · score 0.04
- hepatocellular carcinoma · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8N4L2-F1 | alphafold | PREDICTED | 72.47 | — |
Amino-acid sequence (257 residues)
MAADGVDERS PLLSASHSGN VTPTAPPYLQ ESSPRAELPP PYTAIASPDA SGIPVINCRV CQSLINLDGK LHQHVVKCTV CNEATPIKNP PTGKKYVRCP CNCLLICKDT SRRIGCPRPN CRRIINLGPV MLISEEQPAQ PALPIQPEGT RVVCGHCGNT FLWMELRFNT LAKCPHCKKI SSVGSALPRR RCCAYITIGM ICIFIGVGLT VGTPDFARRF RATYVSWAIA YLLGLICLIR ACYWGAIRVS YPEHSFA
Explore Type 2 phosphatidylinositol 4,5-bisphosphate 4-phosphatase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets